You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. High-specificity affinity reagents for N-glycosylation site mapping and glycomics

    SBC: GLYCOSENSORS AND DIAGNOSTICS, LLC            Topic: 300

    DESCRIPTION Glycans have several distinct properties that make them excellent targets for disease biomarkers Firstly the location of the glycans on the cell surface makes them the first point of contact of cellular interactions and thus crucial in the control of normal metabolic processes Cell surface molecules are also strategically exposed for surveillance by the immune system allowing for ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Phase II SBIR: Responding to NDM-1- Advancement of a new MBL inhibitor to IND

    SBC: VenatoRx Pharmaceuticals, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Multi drug resistance in Enterobacteriaceae is regarded as a healthcare crisis While carbapenems are among the most prescribed antibiotics for infections caused by these organisms carbapenem resistance conferred by zinc based metallo carbapenemases Amber Class B is a growing global health concern that threatens to erode the efficacy of these antibiotics both in th ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Preserving beta-lactam utility vs pathogens producing any class of beta-lactamase

    SBC: VenatoRx Pharmaceuticals, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Multi drug resistance in Enterobacteriaceae is regarded as a healthcare crisis This crisis has been further amplified by the recent emergence of the NDM andquot super bug geneandquot a zinc based metallo lactamase Amber Class B in Enterobacteriaceae Members of this family of resistance enzymes are found on promiscuous plasmids with other MDR resistance mechanisms ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Development of a Urine Test for the Early Detection of Liver Cancer

    SBC: JBS SCIENCE INC.            Topic: NCI

    DESCRIPTION provided by applicant Development of a urine test for the early detection of liver cancer The need to develop an effective method of detecting hepatocellular carcinoma HCC is urgent HCC is the third leading cause of cancer deaths and has a year survival rate of less than If HCC is identified early the survival rate can be as high as The survival rate drops significantly however to as l ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Stimulating Young Neuroscientists And Physiologists in Science Education- Phase

    SBC: IS3D LLC            Topic: 101

    DESCRIPTION provided by applicant This project will develop a suite of innovative learning experiences that will engage high school students in neuroscience and thereby increase their interest in possible careers in this area This will be achieved by creating highly interactive and immersive products developed in partnership with neuroscience experts science teachers and science education re ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  6. An Automated Platform for High-throughput Network Electrophysiology

    SBC: Axion Biosystems, Inc.            Topic: 102

    DESCRIPTION provided by applicant In response to the program announcement for Phase IIb proposals for complex in vitro brain and behavior tools PA this proposed study automates all aspects of in vitro Microelectrode Array MEA technology to deliver the first ever high throughput MEA based screening system This development will not only enable rapid advancements in the study of basi ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Long-Acting G-CSF Analog for Treating ARS

    SBC: BOLDER BIOTECHNOLOGY INC            Topic: NIAID

    DESCRIPTION provided by applicant Development of radiological nuclear medical countermeasures to treat Acute Radiation Syndrome ARS is a high priority research area for NIAID Bone marrow is one of the most sensitive tissues to radiation damage and impaired hematopoiesis is one of the first clinical signs of excessive radiation exposure often resulting i death Granulocyte colony stimulating ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  8. In-Patient Pediatric Gastrojejunal Tube Cleaner Eliminating Surgical Intervention

    SBC: ACTUATED MEDICAL, INC.            Topic: NICHD

    DESCRIPTION provided by applicant In this Phase II NIH SBIR Actuated Medical Inc will complete the development of the Pedi GJ ClearTM device for clearing occlusions and restoring patency in situ to pediatric gastrojejunal feeding tubes GJ tubes eliminating the need to surgically replace clogged tubes Public Health Problem Enteral nutrition is provided for patients that have a functioning lower gas ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Novel liver fibrosis test for early detection and classification

    SBC: IMMUNOTOPE, INC.            Topic: NIAAA

    DESCRIPTION (provided by applicant): The overall goal of this application is to develop and validate a potential biomarker based assay to determine if it can be used as a noninvasive test to detect the stage of hepatic fibrosis and to predict fibrosis progression in HIV/HCV co-infected patients. Significant fibrosis and cirrhosis are premalignant conditions that greatly increase the risk of the de ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. A Diarylheptanoid Scaffold to Treat Taopathies

    SBC: ALS BIOPHARMA, LLC            Topic: NIA

    DESCRIPTION: We identified the Myrica cerifera (Southern Bayberry) extract using a systematic screen as a potent reducer of the structural protein tau, which accumulates in a group of diseases called the tauopathies . The most prevalent tauopathy is Alzheimer's disease, for which there is renewed interest in the identification of tau- based therapeutic approaches to treat this devastating d ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government